Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights

Panelists discuss how the BRAF-KIAA-1549 fusion impacts treatment decisions in cancers like such as low-grade gliomas, emphasizing the role of targeted therapies and the importance of molecular testing for optimal patient disease management.

EP. 1: Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease

December 23rd 2024

Panelists discuss how the treatment approach for relapsed or progressive follicular lymphoma (R/R FL) in the second-line (2L) setting is evolving, focusing on the role of observation vs intervention and the potential impact of ASH 2024 updates, including the inMIND study with tafasitamab and the EPCORE NHL-2 trial with epcoritamab + R2.

EP. 2: Clinical Perspectives Selecting 2L Treatment Options in R/R FL: Chemoimmunotherapy vs Lenalidomide Combinations in Relapsed Disease

January 4th 2025

Panelists discuss how their treatment approaches in the second-line (2L) setting for relapsed or progressive follicular lymphoma (R/R FL) are influenced by factors such as the duration of response to first-line therapy, tumor burden, and symptomatology, while also exploring the use of chemoimmunotherapy, lenalidomide combinations, and anti-CD20 monotherapy in clinical decision-making.